"Chile Pharmaceuticals & Healthcare Report Q4 2014" Published

From: Fast Market Research, Inc.
Published: Tue Oct 28 2014

Improving standards of intellectual property protection will provide incentives for both local and foreign pharmaceutical companies to have long-term strategies in Chile. In addition, Chile's open economy, relatively efficient legal framework, business-friendly environment and local drugmakers' strong Latin American presence will continue to attract multinational investment in the country.

Headline Expenditure Projections

* Pharmaceuticals: CLP1,724bn (USD3.5bn) in 2013 to CLP1,849bn (USD3.29bn) in 2014; +7.3% in local currency terms and -5.4% in US dollar terms.
* Healthcare: CLP10,237bn (USD20.66bn) in 2013 to CLP11,161bn (USD19.86bn) in 2014; +9.0% in local currency terms and -3.9% in US dollar terms.

Risk/Reward Rating

Chile's RRR score for Q414 is 56.3 out of 100, with the company ranked sixth out of the 18 markets in the Americas matrix. This figure is unchanged from Q314.

Full Report Details at
- http://www.fastmr.com/prod/888516_chile_pharmaceuticals_healthcare_report_q4_2014.aspx?afid=303

Key Trends And Developments

* In July 2014, Chilean authorities put a policy in place, which alters decree 466/84 and applies to pharmacies, drug stores, pharmaceutical stores, kits and authorised areas. It requests the reduction of excessive drug use and a move to a more transparent pharmaceutical market.
* In May 2014, Abbott Laboratorie acquired CFR Pharmaceuticals. Abbott expects the acquisition to add approximately USD900mn to its sales in the first full year (2015), with expected double-digit sales growth over the next several years.
* In May 2014, Mexico-based Grupo Casa Saba (GCS) agreed to sell its pharmaceutical retail business to Alliance Boots. The transaction requires Alliance Boots to launch an all-cash tender offer for the outstanding fully diluted share capital of Farmacias Ahumada (FASA), which is listed on Chile's Santiago Stock Exchange. Currently, Casa Saba holds 97.89% of FASA's shares. The transaction was expected to be completed in Q314..

BMI Economic View: Deteriorating investor sentiment and an ongoing slowdown in private...

The Chile Pharmaceuticals & Healthcare Report features Business Monitor International (BMI)'s forecasts for drugs and healthcare expenditure and imports and exports, focusing on the growth outlook for the prescription, OTC, patented drugs and generics market segments.

BMI's Chile Pharmaceuticals & Healthcare Report provides industry professionals, strategists, company executives, investors, analysts and sales/marketing heads with independent forecasts and competitive intelligence on the Chilean pharmaceutical and healthcare industry.

Key Benefits

* Benchmark BMI's independent pharmaceutical and healthcare industry forecasts for Chile to test other views - a key input for successful budgeting and strategic business planning in the Chilean pharmaceutical and healthcare market.

About Fast Market Research

Fast Market Research is a leading distributor of market research and business information. Representing the world's top research publishers and analysts, we provide quick and easy access to the best competitive intelligence available. Our unbiased, expert staff is always available to help you find the right research to fit your requirements and your budget.

For more information about these or related research reports, please visit our website at http://www.fastmr.com or call us at 1.800.844.8156.

You may also be interested in these related reports:

- South Korea Pharmaceuticals & Healthcare Report Q4 2014
- Sweden Pharmaceuticals & Healthcare Report Q4 2014
- Greece Pharmaceuticals & Healthcare Report Q4 2014
- Saudi Arabia Pharmaceuticals & Healthcare Report Q4 2014
- Kenya Pharmaceuticals & Healthcare Report Q4 2014

Company: Fast Market Research, Inc.
Contact Name: Bill Thompson
Contact Email: press@fastmr.com
Contact Phone: 1-413-485-7001

Visit website »